Katja Porvari

Dr. Katja Porvari

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2011 in Journal of Forensic Sciences
Verified
Journal Article
Closed access
PDF file
LPLasse Pakanen
Lasse Pakanen
MKMarja-Leena Kortelainen
Marja-Leena Kortelainen
TSTerttu Särkioja
Terttu Särkioja
KPKatja Porvari
Katja Porvari

1 December 2011 in American Journal of Forensic Medicine & Pathology
Verified
Journal Article
Closed access
MKMarja-Leena Kortelainen
Marja-Leena Kortelainen
KPKatja Porvari
Katja Porvari
Extreme obesity is a strong predictor of premature death, but the prevalence of cardiovascular disease in morbidly obese populations is largely unknown. The aim of the present study was to find out whether there has been an increase in extreme obesity with body mass index 40.0 kg/m(2) or greater in medicolegal autopsy material in a known geographical area in Finland during a period of 3 decades and to examine the prevalence and time trends of associated cardiovascular disease in this obesity category. Autopsy reports of 235 cases examined in 1975 to 2006 were analyzed. The number of extremely obese individuals increased from 0.6% of the yearly amount of autopsies in the 1970s and 1980s to 2.8% and 2.5% in 2005 and 2006, respectively. The most frequent cause of death was cardiomyopathy or cardiomegaly (28.9%), followed by coronary heart disease (24.3%). Either coronary arteries were lesion-free, or only fatty streaks had been observed in 46.8% of the women and in 43.1% of the men. No significant changes in the average body mass index or severity of coronary atherosclerosis were observed. Younger individuals younger than 40 years began to appear more often after 1995. An increased trend of extreme obesity in a region where autopsy frequency is high may refer to a general increase of this obesity category. A large number of extremely obese people are resistant to coronary atherosclerosis, but cardiac hypertrophy may be accompanied by several mechanisms leading to sudden death even among the youngest extremely obese individuals.

1 February 1997 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
AHAnnakaisa Herrala
Annakaisa Herrala
RKRiitta Kurkela
Riitta Kurkela
KPKatja Porvari
Katja Porvari
RIRitva Isomäki
Ritva Isomäki
PHPirkko Henttu
Pirkko Henttu
PVPirkko Vihko
Pirkko Vihko
A polymorphism in the human prostate-specific glandular kallikrein (hKLK2) gene was described by direct sequencing (by PCR) of genomic DNAs isolated from prostatic cancer tissue, benign prostatic hyperplasia tissue, and blood leukocyte specimens. Results showed two forms of human prostate-specific glandular kallikrein protein (hK2), a consequence of a change from C to T at base 792 in the hK2 coding region. Producing the two forms as recombinant proteins in insect cells demonstrated that Arg226-hK2 (CC genotype) is an active protein and Trp226-hK2 (TT genotype) is inactive. Polymorphism studies of 36 patients with prostatic diseases identified only 1 with the TT genotype. The same kind of polymorphism was not detected in the human prostate-specific antigen (hKLK3) gene. Arg226-hK2 possessed only trypsin-like enzyme activity, whereas recombinant human prostate-specific antigen (hPSA) had only chymotrypsin-like activity. Monoclonal and polyclonal antibodies raised against hPSA purified from seminal plasma detected both active and inactive hK2. Thus, because inactive as well as stable hK2 protein may be present, a lack of trypsin-like activity in hPSA standards is not enough to confirm that the materials are free of hK2 contamination.

23 March 2019 in International journal of legal medicine
Verified
Journal Article
Open access
PDF file
HKHelena Kaija
Helena Kaija
LPLasse Pakanen
Lasse Pakanen
KPKatja Porvari
Katja Porvari
Here, we tested the usefulness of small non-coding RNAs as references in quantitative RT-PCR expression analyses in hypothermia and chronic cardiac ischemia as the primary causes of death. Cq values of RNU6B, SCARNA17, SNORD25, and SNORA73A were determined from human cadaver samples of hypothermia and cardiac deaths. Average Cq values of RNU6B were higher in hypothermic and average SCARNA17 Cq values in chronic ischemic samples, but no difference in SNORD25 and SNORA73A Cq values could be seen between the groups. RNU6B expression levels were calculated using SNORD25, SNORA73A, and their combination as the reference in normalization. Expression of RNU6B, a widely used reference, was found to be significantly lower in hypothermia than in chronic cardiac ischemia. In these conditions, RNU6B is a useful marker differentiating hypothermia deaths from chronic ischemic heart disease deaths, but not a valid reference for normalization in expression studies.

9 September 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
PKPeeter Karihtala
Peeter Karihtala
KPKatja Porvari
Katja Porvari
NRNelli Roininen
Nelli Roininen
SVSari Voutilainen
Sari Voutilainen
JMJohanna Mattson
Johanna Mattson
KSKatri Selander
Katri Selander
The pathophysiology and the optimal treatment of breast neuroendocrine tumours (NETs) are unknown. We compared the mutational profiles of breast NETs (n = 53) with those of 724 publicly available invasive ductal carcinoma (IDC) and 98 pancreatic NET (PNET) cases. The only significantly different pathogenetic or unknown variant rate between breast NETs and IDCs was detected in theTP53(11.3% in breast NETs and 41% in IDCs, adjustedpvalue 0.027) andADCK2(9.4% in breast NETs vs. 0.28% in IDCs, adjustedpvalue 0.045) genes. Between breast NETs and PNETs, different pathogenetic or unknown variant frequencies were detected in 30 genes. For example,MEN1was mutated in only 6% of breast NETs and 37% in PNETs (adjustedpvalue 0.00050), andGATA3pathogenetic or unknown variants were only found in 17.0% of breast NETs and 0% in PNETs (adjustedpvalue 0.0010). The most commonly affected oncogenic pathways in the breast NET cases werePI3K/Akt/mTOR,NOTCHandRTK-RASpathways. Breast NETs had typically clock-like mutational signatures and signatures associated with defective DNA mismatch repair in their mutational landscape. Our results suggest that the breast NET mutational profile more closely resembles that of IDCs than that of PNETs. These results also revealed several potentially druggable targets, such as MMRd, in breast NETs. In conclusion, breast NETs are indeed a separate breast cancer entity, but their optimal treatment remains to be elucidated.

28 December 2014 in International journal of legal medicine
Verified
Journal Article
Closed access
PDF file
LPLasse Pakanen
Lasse Pakanen
HKHelena Kaija
Helena Kaija
MKMarja-Leena Kortelainen
Marja-Leena Kortelainen
TSTerttu Särkioja
Terttu Särkioja
KPKatja Porvari
Katja Porvari